Skip to main content

Regencell Bioscience Holdings Limited (RGC)

NASDAQ: RGC · IEX Real-Time Price · USD
17.79 -0.31 (-1.69%)
Oct 21, 2021 12:49 PM EDT - Market open
Market Cap224.84M
Revenue (ttm)n/a
Net Income (ttm)n/a
Shares Out12.64M
EPS (ttm)n/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume31,255
Open18.04
Previous Close18.09
Day's Range17.67 - 19.16
52-Week Range6.00 - 59.00
Betan/a
Analystsn/a
Price Targetn/a
Est. Earnings Daten/a

About RGC

Regencell Bioscience is an early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine (\"TCM\") for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder (“ADHD”) and Autism Spectrum Disorder (“ASD”). Our goal is to improve the lives of ADHD and ASD patients, their families and caregivers and become a market leader for the best treatment of ADHD and ASD globally. We have three standardized TCM formulae candidates u...

IndustryDrug Manufacturers-Specialty & Generic
IPO DateJul 16, 2021
CEOYat-Gai Au
CountryHong Kong
Stock ExchangeNASDAQ
Ticker SymbolRGC
Full Company Profile

Financial Performance

Financial Statements

News

Regencell Bioscience Stock Jumps On Formation Of COVID-19 Treatment Focused Joint Venture

Regencell Bioscience Holdings Ltd's (NASDAQ: RGC) subsidiary in Hong Kong has entered into a joint venture agreement with Honor Epic Enterprises Limited to offer COVID-19 related treatments. The joint v...

1 month ago - Benzinga

Regencell Bioscience Holdings Limited Establishes a Joint Venture to Offer COVID Treatment

HONG KONG--(BUSINESS WIRE)--Regencell Bioscience Holdings Limited (NASDAQ: RGC) (“Regencell” or the “Company”), today announced that Regencell Bioscience Limited (“Regencell HK”), the Company's wholly-o...

1 month ago - Business Wire

Is RGC Stock Rallying On Mistaken Identity?

Will RGC Stock Crash Or Go Higher After Today? The post Is RGC Stock Rallying On Mistaken Identity?

2 months ago - PennyStocks

Regencell Bioscience Holdings Limited Announces Partial Exercise of Underwriter's Over-Allotment Option

HONG KONG--(BUSINESS WIRE)--Regencell Bioscience Holdings Limited (NASDAQ:RGC) ("Regencell" or the "Company"), an early-stage bioscience company that focuses on research, development and commercializati...

2 months ago - Business Wire

Regencell Bioscience Holdings Limited Releases CEO Letter to Shareholders

HONG KONG--(BUSINESS WIRE)--Regencell Bioscience Holdings Limited (NASDAQ: RGC) (“Regencell” or the “Company”), an early-stage bioscience company today released a letter from Yat-Gai Au, Founder and Chi...

2 months ago - Business Wire

Regencell Bioscience Holdings Limited Announces Closing of Initial Public Offering

Regencell Bioscience Holdings Limited (NASDAQ:RGC) (“Regencell” or the “Company”), an early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Me...

3 months ago - Business Wire

Regencell Bioscience Holdings Limited Announces Pricing of Approximately $21.9 Million Initial Public Offering

Regencell Bioscience Holdings Limited (NASDAQ:RGC) (“Regencell” or the “Company”), an early-stage bioscience company that focuses on research, development...

3 months ago - Business Wire

Chinese drug developer Regencell Bioscience files for an $18 million US IPO

Regencell Bioscience Holdings, which is developing formulations of traditional Chinese medicine for ADHD and ASD, filed on Monday with the SEC to raise up to $18 million in an initial public offering.

6 months ago - NASDAQ

Regencell Bioscience IPO Registration Document (S-1_

Regencell Bioscience has filed to go public with an IPO on the NASDAQ.

6 months ago - SEC